Starboard's words were echoed by Gregg Gilbert, an analyst at Deutsche Bank.
In a research report on Tuesday, Gilbert stated that he upgraded Perrigo's stock on July 22 based on the premise that investors would re-focus on Perrigo as a "company with decent growth prospects and durable cash flows."
The analyst also suggested that after meeting with Perrigo's management team, the senior executives are now "more open-minded than ever" to consider strategic alternatives and the timing of Starboard's involvement could help create "multiple routes to value enhancement from the current price."
Gilbert also studied the math behind some of Starboard's suggestions, including the sale of Rx Pharma and/or Tysabri. Here is what the analyst wrote:
"For this analysis, we started with theoretical sale proceeds based on acquisition multiples for Rx Pharma (yields $5.4 billion) and our DCF model for Tysabri (yields $3.1 billion). We applied part of the proceeds to pay down debt in order to maintain a leverage ratio in 2017 similar to our estimate for the overall company, and the balance for share repurchases to offset EPS dilution.
"Our preliminary analysis for the separation of both segments yields EPS dilution of ~22 percent/16 percent/12 percent/10 percent in 2017/18/19/20. The EPS dilution could be more than offset by P/E multiple expansion as investors tend to pay significantly higher multiples for consumer-facing businesses with durable cashflow potential."
Shares of Perrigo remain Buy rated with an unchanged $105 price target.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.